Oral Answers to Questions

Paul Flynn Excerpts

Monday 15th July 2013 Commons Chamber

[Mr Browne]

I pay tribute to my hon. Friend for the interest that she takes in this important issue in her constituency. It is important for everyone to understand that it is not the name or the packaging of the product that is banned, but the group of chemical compounds that gives the drug its characteristics. Changing the packaging will not change the legal status of the drug, and law enforcement officers in my hon. Friend’s constituency and elsewhere should proceed on that basis.

[Paul Flynn (Newport West) (Lab)]

Banning the designer drug mephedrone resulted in a 300% increase in its use. Banning khat is likely to have the same effect. Has the Minister examined the report of the all-party group on drug policy reform that suggested the New Zealand proposal, which is intelligent and practical and is likely to lead to a reduction in use?

[Mr Browne]

I spent over an hour last week speaking to the New Zealand Health Minister about precisely this subject. It is a very interesting area of policy development and we will study carefully what is happening in New Zealand and the policy there. I should offer a word of caution, however, to the hon. Gentleman, who has a long record of campaigning on the issue. Over recent years, we have seen quite big falls in the use of some of the most serious illegal drugs—heroin and crack cocaine—so the illegal status of those drugs does not appear to have led to the rise in use, as he claims would be the case.